- Abbott initiated pivotal trial for Cephea device
- Device targets mitral heart valve disease
- Abbott announced the initiation of a pivotal clinical trial for its Cephea device, designed to treat mitral heart valve disease.
Abbott started a pivotal trial for its Cephea device targeting mitral heart valve disease. The trial could support future regulatory approval and expand Abbott's structural heart portfolio.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.